For Research Use Only. Not for human consumption. The following summarizes published preclinical literature for laboratory research purposes only.
What It Is
Sermorelin is the synthetic acetate salt of GHRH(1-29)-NH2, corresponding to the first 29 amino acids of the 44-amino-acid endogenous human growth hormone-releasing hormone — the shortest fragment of native GHRH retaining full biological activity. It is classified in the literature as a GHRH-receptor agonist, historically developed and commercialized by Serono Laboratories under the brand name Geref (FDA product history).
Summary of Published Research Findings
Sermorelin’s core pharmacology derives from foundational GHRH research establishing that the 1-29 fragment retains the full GH-releasing potency of the intact 44-amino-acid hormone, acting directly on anterior pituitary somatotroph receptors. Early receptor-binding and pituitary cell-culture studies characterizing GHRH(1-29) demonstrated dose-dependent stimulation of GH secretion from cultured pituitary cells, forming the pharmacological reference point for subsequent GHRH-analog characterization work (historical GHRH research — noting GHRH(1-29) as the parent structure from which longer-acting analogs such as CJC-1295 were subsequently derived).
Sermorelin has a distinctive regulatory history: it is one of the few synthetic GHRH analogs to have received FDA approval, with that approval voluntarily withdrawn from the U.S. market by Serono in 2008 for commercial rather than safety reasons; its documented pharmacological role in that era was as a pituitary-function research and assessment tool (FDA drug withdrawal database). This regulatory history is referenced here strictly as research/background context.
Mechanistically related pituitary-cell research, including the same line of investigation that led to development of longer-acting GHRH analogs, used cultured rat anterior pituitary cells to demonstrate that GHRH(1-29) derivatives reliably activate the GHRH receptor and trigger measurable GH secretion in vitro, establishing sermorelin’s parent structure as the pharmacological reference point for the broader GHRH-analog research field (Jetté et al., Endocrinology, 2005).
Proposed Mechanism of Action
Sermorelin is proposed to act as a direct agonist at the GHRH receptor on pituitary somatotroph cell membranes, activating adenylate cyclase and increasing intracellular cyclic AMP, which stimulates GH gene transcription and pulsatile GH secretion. Because it corresponds to a naturally occurring truncated fragment of GHRH rather than a chemically extended analog, its duration of receptor engagement in the literature is characterized as shorter than modified analogs such as CJC-1295 or tesamorelin.
Research Use Only / Handling Note
Sermorelin acetate for laboratory research is supplied as a lyophilized powder. This RUO product is intended exclusively for qualified laboratory research applications and is not intended for human or animal administration.